Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 2565 (117th)

FDA Modernization Act of 2021

referredUnited States· United States Congress· EN

Introduced

15 April 2021

Last action

16 April 2021 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Buchanan, Vern [R-FL-16], Rep. Luria, Elaine G. [D-VA-2], Rep. Mace, Nancy [R-SC-1], Rep. Sherrill, Mikie [D-NJ-11], Rep. Boyle, Brendan F. [D-PA-2], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Cole, Tom [R-OK-4], Rep. Fallon, Pat [R-TX-4], Rep. Salazar, Maria Elvira [R-FL-27], Rep. DeLauro, Rosa L. [D-CT-3], Rep. Quigley, Mike [D-IL-5], Rep. DeFazio, Peter A. [D-OR-4], Rep. Lieu, Ted [D-CA-36], Rep. Moore, Barry [R-AL-1], Rep. Carter, Earl L. "Buddy" [R-GA-1], Rep. Fletcher, Lizzie [D-TX-7], Rep. Burchett, Tim [R-TN-2], Rep. Gottheimer, Josh [D-NJ-5], Rep. Harshbarger, Diana [R-TN-1], Rep. Grothman, Glenn [R-WI-6], Rep. Katko, John [R-NY-24], Rep. Malinowski, Tom [D-NJ-7], Rep. Titus, Dina [D-NV-1], Rep. Malliotakis, Nicole [R-NY-11], Rep. Barragán, Nanette Diaz [D-CA-44], Rep. Gimenez, Carlos A. [R-FL-28], Rep. Calvert, Ken [R-CA-41], Lisa McClain, Rep. Stevens, Haley M. [D-MI-11], Rep. Waltz, Michael [R-FL-6], Rep. Cárdenas, Tony [D-CA-29], Rep. Kaptur, Marcy [D-OH-9], Rep. Sessions, Pete [R-TX-17], Rep. Krishnamoorthi, Raja [D-IL-8], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Smith, Christopher H. [R-NJ-4], Rep. Pappas, Chris [D-NH-1], Rep. Carter, Troy A. [D-LA-2], Rep. Jones, Mondaire [D-NY-17], Rep. Levin, Andy [D-MI-9], Rep. McNerney, Jerry [D-CA-9], Rep. Gooden, Lance [R-TX-5], Rep. Harder, Josh [D-CA-9], Colin Allred, Rep. Valadao, David G. [R-CA-22], Rep. Garbarino, Andrew R. [R-NY-2], Madison Cawthorn, Rep. Neguse, Joe [D-CO-2]

Subjects

Healthcare

Source updated

7 April 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

FDA Modernization Act of 2021 This bill allows an applicant for market approval for a new drug to use methods other than animal testing to establish the drug's safety and effectiveness. Under this bill, these alternative methods may include cell-based assays, organ chips and microphysiological systems, sophisticated computer modeling, and other human biology-based test methods.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 15 April 2021

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 15 April 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 15 April 2021

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 16 April 2021

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 15 April 2021

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 15 April 2021

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 15 April 2021

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 116 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.